XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues [Abstract]      
Revenue $ 321,793 $ 296,397 $ 192,194
Operating expenses:      
Research and development 90,388 76,525 48,941
Sales and marketing 96,027 77,245 53,858
General and administrative 100,397 74,964 48,806
Total operating expenses 399,024 326,123 214,722
Loss from operations (77,231) (29,726) (22,528)
Other income (expense):      
Interest income, net 3,762 160 271
Change in estimated fair value of common stock warrant liability 107 106 (1,495)
CARES Act Provider Relief Fund 0 0 4,813
Other expense, net (2,872) (2,628) (811)
Total other income (expense) 997 (2,362) 2,778
Loss before income taxes (76,234) (32,088) (19,750)
Income tax (expense) benefit (379) 1,426 1,036
Net loss $ (76,613) $ (30,662) $ (18,714)
Net loss per share (Note 3):      
Basic (in dollars per share) $ (1.44) $ (0.59) $ (0.40)
Diluted (in dollars per share) $ (1.44) $ (0.59) $ (0.40)
Weighted-average shares used to compute net loss per share:      
Basic (in shares) 53,321,625 52,241,076 46,481,772
Diluted (in shares) 53,321,625 52,241,076 46,481,772
Testing services revenue      
Revenues [Abstract]      
Revenue $ 263,748 $ 259,285 $ 163,610
Operating expenses:      
Cost of testing services, product, patient and digital solutions 72,286 71,251 43,932
Product revenue      
Revenues [Abstract]      
Revenue 29,251 26,832 19,302
Operating expenses:      
Cost of testing services, product, patient and digital solutions 17,639 18,930 13,847
Patient and digital solutions      
Revenues [Abstract]      
Revenue 28,794 10,280 9,282
Operating expenses:      
Cost of testing services, product, patient and digital solutions $ 22,287 $ 7,208 $ 5,338